We’re Keeping An Eye On Cloudbreak Pharma’s (HKG:2592) Cash Burn Rate

Even when a business is losing money, it’s possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you’d have done very well indeed. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

So should Cloudbreak Pharma (HKG:2592) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let’s start with an examination of the business’ cash, relative to its cash burn.

We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

When Might Cloudbreak Pharma Run Out Of Money?

A company’s cash runway is calculated by dividing its cash hoard by its cash burn. As at December 2025, Cloudbreak Pharma had cash of US$58m and such minimal debt that we can ignore it for the purposes of this analysis. Looking at the last year, the company burnt through US$52m. So it had a cash runway of approximately 14 months from December 2025. While that cash runway isn’t too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. You can see how its cash balance has changed over time in the image below.

Check out our latest analysis for Cloudbreak Pharma

How Is Cloudbreak Pharma’s Cash Burn Changing Over Time?

While Cloudbreak Pharma did record statutory revenue of US$253k over the last year, it didn’t have any revenue from operations. To us, that makes it a pre-revenue company, so we’ll look to its cash burn trajectory as an assessment of its cash burn situation. During the last twelve months, its cash burn actually ramped up 94%. While this spending increase is no doubt intended to drive growth, if the trend continues the company’s cash runway will shrink very quickly. Admittedly, we’re a bit cautious of Cloudbreak Pharma due to its lack of significant operating revenues. We prefer most of the stocks on this list of stocks that analysts expect to grow.

Can Cloudbreak Pharma Raise More Cash Easily?

While Cloudbreak Pharma does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company’s cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year’s cash burn.

Cloudbreak Pharma has a market capitalisation of US$126m and burnt through US$52m last year, which is 41% of the company’s market value. That’s high expenditure relative to the value of the entire company, so if it does have to issue shares to fund more growth, that could end up really hurting shareholders returns (through significant dilution).

How Risky Is Cloudbreak Pharma’s Cash Burn Situation?

Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Cloudbreak Pharma’s cash runway was relatively promising. Summing up, we think the Cloudbreak Pharma’s cash burn is a risk, based on the factors we mentioned in this article. On another note, Cloudbreak Pharma has 4 warning signs (and 3 which are significant) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts)

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.